Osaka University Hospital in Japan has scanned the first patient with MedTrace's PET tracer system.
The hospital was one of the first institutions to make an agreement with MedTrace on positron-emitting isotope oxygen-15 (O-15)-labeled water research. The company said its ongoing phase III trial focuses on using the isotope to visualize coronary artery disease.
The company also wants to investigate O-15 water's potential for measuring tumor blood flow in patients with lung cancer before chemotherapy and to assess whether tumor blood flow is a predictive factor of chemotherapy, MedTrace said.
